• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自 2010 年以来,美国、澳大利亚和新西兰的卵母细胞冷冻保存周期显著增加,主要是年轻女性推动的,但需要标准化的数据收集。

A major increase in oocyte cryopreservation cycles in the USA, Australia and New Zealand since 2010 is highlighted by younger women but a need for standardized data collection.

机构信息

Department of Obstetrics and Gynaecology, Monash University, Clayton, Australia.

Boston IVF, Waltham, MA, USA.

出版信息

Hum Reprod. 2021 Feb 18;36(3):624-635. doi: 10.1093/humrep/deaa320.

DOI:10.1093/humrep/deaa320
PMID:33367704
Abstract

STUDY QUESTION

What are the cohort trends of women undergoing oocyte cryopreservation (OC)?

SUMMARY ANSWER

There has been a dramatic increase in OC cycles undertaken each year since 2010, and the demographics of women accessing OC has shifted to a younger age group, but so far very few women have returned to use their cryopreserved oocytes in treatments.

WHAT IS KNOWN ALREADY

Although OC, as a method of fertility preservation, is offered around the world, global data are lacking on who is accessing OC, who is returning to thaw oocytes and whether these trends are changing.

STUDY DESIGN, SIZE, DURATION: A trinational retrospective cohort study was performed of 31 191 OC cycles and 972 oocyte thaw (OT) cycles undertaken in the USA (2010-2016) and 3673 OC and 517 OT cycles undertaken in Australia/New Zealand (Aus/NZ; 2010-2015).

PARTICIPANTS/MATERIALS, SETTING, METHODS: Data were obtained from the USA Society for Assisted Reproductive Technology (SART) national registry and the Australian and New Zealand Assisted Reproduction Database (ANZARD). De-identified data were requested on all autologous oocyte freeze-all cycles and all cycles where autologous oocytes were thawed to be used in a treatment cycle for the time periods of interest.

MAIN RESULTS AND THE ROLE OF CHANCE

In both the USA and Aus/NZ, there has been a dramatic rise in the number of OC cycles performed each year (+880% in the USA from 2010 to 2016 and +311% in Aus/NZ from 2010 to 2015). Across both regions, most women undergoing OC were aged in their late 30s, but the average age decreased over time (USA: 36.7 years vs 34.7 years in 2010 and 2016, respectively). The number of women returning for thaw cycles was low (USA: 413 in 2016, Aus/NZ: 141 in 2015) and most thaw cycles (47%) across both regions involved oocytes that were frozen for <6 months. In the USA, a higher proportion of cycles resulted in a live birth when only thawed oocytes were used, compared to cycles that combined thawed oocytes with fresh oocytes (25% vs 11%, respectively; P < 0.001). Age at retrieval influenced live birth rate in the USA; 38% of thaw cycles started in women who stored oocytes when aged ≤35 years resulted in a live birth, whereas only 16% resulted in a live birth for women who stored oocytes when aged ≥36 years. Similar data were unobtainable from Aus/NZ.

LIMITATIONS, REASONS FOR CAUTION: There were limitations associated with both the SART and ANZARD data outputs received. The format in which the ANZARD data were provided, and the inconsistencies seen amongst cycle reporting in the SART dataset, restricted data interpretation. For example, both datasets did not provide a clear indication as to why women were undergoing OC and it was not possible to accurately calculate duration of storage for thaw cycles in the USA. We also did not obtain details on embryo quality from either database and acknowledge that embryo quality and subsequent outcome (embryo freezing or discard) would be of interest, especially when considering the efficacy of OC.

WIDER IMPLICATIONS OF THE FINDINGS

The data show that there is widespread demand for OC, and it is increasingly undertaken by younger women; however, the limitations encountered in the dataset support the need for a shift to a more uniform approach to data collection and presentation by large databases, worldwide.

STUDY FUNDING/COMPETING INTEREST(S): This study received funding from the Fertility Society of Australia to support the ANZARD data extraction. M.J. is supported by an Australian Government Research Training Program Scholarship stipend. The authors declare no competing interests.

TRIAL REGISTRATION NUMBER

N/A.

摘要

研究问题

接受卵子冷冻保存(OC)的女性队列趋势是什么?

总结答案

自 2010 年以来,每年进行的 OC 周期数量急剧增加,接受 OC 的女性的人口统计学特征已转移到更年轻的年龄组,但到目前为止,很少有女性返回使用她们冷冻的卵子进行治疗。

已知情况

尽管 OC 作为一种生育力保存方法在全球范围内提供,但缺乏关于谁在接受 OC、谁在解冻卵子以及这些趋势是否在变化的全球数据。

研究设计、大小、持续时间:在美国(2010-2016 年)和澳大利亚/新西兰(Aus/NZ;2010-2015 年)进行了一项跨国回顾性队列研究,涉及 31191 个 OC 周期和 972 个卵子解冻(OT)周期,以及 3673 个 OC 和 517 个 OT 周期。

参与者/材料、设置、方法:从美国辅助生殖技术协会(SART)国家注册处和澳大利亚/新西兰辅助生殖数据库(ANZARD)获得数据。请求了所有自体卵冷冻全部周期和所有使用自体卵解冻的治疗周期的匿名数据。

主要结果和机会的作用

在美国和 Aus/NZ ,每年进行的 OC 周期数量都急剧增加(2010 年至 2016 年在美国增加了 880%,在 Aus/NZ 增加了 311%)。在这两个地区,大多数接受 OC 的女性年龄在 30 多岁,但随着时间的推移,平均年龄下降(美国:36.7 岁 vs 2010 年和 2016 年的 34.7 岁)。返回解冻周期的女性数量很少(美国:2016 年有 413 人,Aus/NZ 年有 141 人),而且大多数解冻周期(47%)涉及冷冻时间<6 个月的卵子。在美国,与将解冻卵子与新鲜卵子结合使用的周期相比,仅使用解冻卵子的周期更有可能导致活产(25%对 11%;P<0.001)。在 USA ,取卵时的年龄影响活产率;在≤35 岁时储存卵子的女性中,38%的解冻周期导致活产,而≥36 岁时储存卵子的女性中只有 16%导致活产。Aus/NZ 无法获得类似的数据。

局限性、谨慎的原因:收到的 SART 和 ANZARD 数据输出都存在局限性。收到的 ANZARD 数据的格式以及 SART 数据集在周期报告中的不一致性限制了数据解释。例如,两个数据集都没有明确说明女性为什么要进行 OC,也不可能准确计算美国解冻周期的储存时间。我们也没有从任何一个数据库中获得胚胎质量的详细信息,并承认胚胎质量和随后的结果(胚胎冷冻或丢弃)将是人们关注的焦点,尤其是在考虑 OC 的效果时。

研究结果的更广泛意义

数据表明,对 OC 的需求广泛,越来越多的年轻女性接受 OC;然而,在数据集遇到的限制支持需要在全球范围内向大型数据库更统一地收集和呈现数据的方法转变。

研究资助/利益冲突:这项研究得到了澳大利亚生育协会的资助,以支持 ANZARD 数据提取。MJ 得到了澳大利亚政府研究培训计划奖学金的支持。作者没有利益冲突。

试验注册编号

无。

相似文献

1
A major increase in oocyte cryopreservation cycles in the USA, Australia and New Zealand since 2010 is highlighted by younger women but a need for standardized data collection.自 2010 年以来,美国、澳大利亚和新西兰的卵母细胞冷冻保存周期显著增加,主要是年轻女性推动的,但需要标准化的数据收集。
Hum Reprod. 2021 Feb 18;36(3):624-635. doi: 10.1093/humrep/deaa320.
2
The number of oocytes associated with maximum cumulative live birth rates per aspiration depends on female age: a population study of 221 221 treatment cycles.与每个抽吸相关的最大累积活产率相关的卵母细胞数量取决于女性年龄:221221 个治疗周期的人群研究。
Hum Reprod. 2019 Sep 29;34(9):1778-1787. doi: 10.1093/humrep/dez100.
3
Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.1050名女性在一个辅助生殖技术周期(包括所有后续冻融周期)后的累积活产率:一项比较促性腺激素释放激素拮抗剂和促性腺激素释放激素激动剂方案的随机对照试验的次要结果。
Hum Reprod. 2017 Mar 1;32(3):556-567. doi: 10.1093/humrep/dew358.
4
Predicting the likelihood of live birth for elective oocyte cryopreservation: a counseling tool for physicians and patients.预测选择性卵母细胞冷冻保存活产的可能性:为医生和患者提供的咨询工具。
Hum Reprod. 2017 Apr 1;32(4):853-859. doi: 10.1093/humrep/dex008.
5
A 10-year follow-up of reproductive outcomes in women attempting motherhood after elective oocyte cryopreservation.选择性卵母细胞冷冻保存后尝试生育的女性的 10 年生殖结局随访。
Hum Reprod. 2024 Feb 1;39(2):355-363. doi: 10.1093/humrep/dead267.
6
Live birth and perinatal outcomes using cryopreserved oocytes: an analysis of the Human Fertilisation and Embryology Authority database from 2000 to 2016 using three clinical models.使用冷冻卵子的活产和围产期结局:2000 年至 2016 年人类受精和胚胎管理局数据库的三种临床模型分析。
Hum Reprod. 2021 Apr 20;36(5):1416-1426. doi: 10.1093/humrep/deaa343.
7
Population trends and live birth rates associated with common ART treatment strategies.与常见辅助生殖技术(ART)治疗策略相关的人口趋势和活产率
Hum Reprod. 2016 Nov;31(11):2632-2641. doi: 10.1093/humrep/dew232. Epub 2016 Sep 22.
8
Frozen eggs: national autologous oocyte thaw outcomes.冷冻卵子:国家自体卵母细胞解冻结局。
Fertil Steril. 2021 Oct;116(4):1077-1084. doi: 10.1016/j.fertnstert.2021.05.080. Epub 2021 Jul 22.
9
Cumulative live birth rates for women returning to ART treatment for a second ART-conceived child.女性因第二个接受 ART 受孕的孩子而返回接受 ART 治疗的累积活产率。
Hum Reprod. 2020 Jun 1;35(6):1432-1440. doi: 10.1093/humrep/deaa030.
10
20 years of the European IVF-monitoring Consortium registry: what have we learned? A comparison with registries from two other regions.20 年的欧洲 IVF 监测联合协会注册研究:我们学到了什么?与另外两个地区的注册研究结果进行比较。
Hum Reprod. 2020 Dec 1;35(12):2832-2849. doi: 10.1093/humrep/deaa250.

引用本文的文献

1
Policy solutions to improve access to fertility treatment and optimise patient care: consensus from an expert forum.改善生育治疗可及性并优化患者护理的政策解决方案:专家论坛共识
Front Reprod Health. 2025 Aug 29;7:1605480. doi: 10.3389/frph.2025.1605480. eCollection 2025.
2
Age-Based Oocyte Yield in Elective Oocyte Cryopreservation: A Retrospective Cohort Study.选择性卵母细胞冷冻保存中基于年龄的卵母细胞产量:一项回顾性队列研究。
Diagnostics (Basel). 2025 Sep 8;15(17):2278. doi: 10.3390/diagnostics15172278.
3
The use of immotile testicular sperm for in vitro fertilization/intracytoplasmic sperm injection: what are the outcomes?
使用无活动力的睾丸精子进行体外受精/卵胞浆内单精子注射:结果如何?
F S Rep. 2025 Mar 18;6(2):108-115. doi: 10.1016/j.xfre.2025.03.005. eCollection 2025 Jun.
4
Nesting the Eggs on Another Day: Social Egg Freezing.择日储卵:社会卵子冷冻
J Obstet Gynaecol India. 2025 Jun;75(3):192-198. doi: 10.1007/s13224-025-02157-x. Epub 2025 May 29.
5
Do women accurately predict their odds of having a child following planned oocyte cryopreservation?女性在计划进行卵母细胞冷冻保存后,能否准确预测自己生育孩子的几率?
Reprod Fertil. 2025 Feb 27;6(1). doi: 10.1530/RAF-24-0118. Print 2025 Jan 1.
6
Development of a novel calculator to predict gonadotropin dose and oocyte yield in oocyte cryopreservation cycles.一种用于预测卵母细胞冷冻保存周期中促性腺激素剂量和卵母细胞产量的新型计算器的开发。
J Assist Reprod Genet. 2025 Feb;42(2):423-432. doi: 10.1007/s10815-024-03372-7. Epub 2025 Jan 7.
7
Duration of cryostorage is not associated with rates of thaw survival, fertilization, blastulation and ploidy, or pregnancy outcomes of vitrified human oocytes.冷冻保存时间与玻璃化人类卵母细胞的解冻存活率、受精率、囊胚形成率、倍性或妊娠结局无关。
J Assist Reprod Genet. 2025 Feb;42(2):525-532. doi: 10.1007/s10815-024-03350-z. Epub 2025 Jan 3.
8
Impact of Systemic Lupus Erythematosus on Conception: Insights into Infertility, Fertility Preservation, Assisted Reproductive Technology, and Pregnancy Outcomes.系统性红斑狼疮对受孕的影响:关于不孕症、生育力保存、辅助生殖技术及妊娠结局的见解
Semin Reprod Med. 2024 Sep;42(3):209-227. doi: 10.1055/s-0044-1793827. Epub 2024 Dec 12.
9
Clinical utilization and outcomes over eight consecutive years following oocyte cryopreservation.卵母细胞冷冻保存后连续八年的临床应用及结果
J Assist Reprod Genet. 2025 Feb;42(2):413-421. doi: 10.1007/s10815-024-03334-z. Epub 2024 Dec 4.
10
Alignment, Anticipation, Adaptation, or Lagging Behind? Age-Based Regulations in Assisted Reproduction and Late Fertility.对齐、预期、适应还是落后?辅助生殖与晚育中基于年龄的规定
Popul Dev Rev. 2024 Dec;50(4):1319-1351. doi: 10.1111/padr.12658. Epub 2024 Sep 30.